Respiratory distress secondary to both amphotericin B deoxycholate and lipid complex formulation.
A 73-y-old female with a history of adenocarcinoma of colon and refractory anemia developed febrile neutropenia following chemotherapy. Therapy with iv infusion of amphotericin B deoxycholate (AmBd) was initiated on day 8 of hospital admission. Premedications included acetaminophen, diphenhydramine and meperidine. Patient developed rigor, chill and elevated temperature approximately 100 min into the infusion. The infusion was temporarily discontinued and rigors subsided following administration of 25 mg meperidine im. Infusion was continued after cessation of the rigors with no further sequelae. During each infusion of AmBd over the next 3 d, the patient developed rigor, chill and elevated temperature which was managed with meperidine. However, on day 4 she developed respiratory distress, bronchospasm and visible cyanosis with oxygen saturation of 88% while on 2 L oxygen. The infusion was stopped and the symptoms subsided with administration of albuterol via nebulizer. Amphotericin lipid formulation infusion was reinstituted after 3 d because of the patient's worsening clinical status. However, the patient developed severe respiratory distress approximately 130 min into the infusion. The infusion was discontinued and she was treated with albuterol via nebulizer. Itraconazole therapy was instituted without any adverse sequelae. Clinicians should be aware of this potential adverse event since it can occur with all formulation of amphotericin.
Rolland
W A
WA
Department of Clinical Pharmacology, State University of New York Health Science Center at Syracuse, 13210, USA.
Guharoy
R
R
Ramirez
L
L
Blair
D
D
Medicis
J
J
Khan
U
U
D000230:Adenocarcinoma / Q000150:complications; D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects*; D000740:Anemia / Q000150:complications; D000935:Antifungal Agents / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000150:complications; D004338:Drug Combinations; D005260:Female; D005334:Fever / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D009503:Neutropenia / Q000188:drug therapy*; D010713:Phosphatidylcholines / Q000009:adverse effects*; D010715:Phosphatidylglycerols / Q000009:adverse effects*; D012128:Respiratory Distress Syndrome / Q000139:chemically induced*
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B